← All trials
NCT03266601
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2016
- Primary completion
- Nov 30, 2018
- Completion date
- Dec 31, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 660
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fudan UniversityLead sponsor
- Fudan UniversityReponsible party - principal investigator
- Chongqing Medical UniversityCollaborator
- Changhai HospitalCollaborator
- Shenzhen UniversityCollaborator
- University of South ChinaCollaborator
- Anhui Medical UniversityCollaborator
- Children's Hospital of Kaifeng CityCollaborator
- Shandong UniversityCollaborator
- Sinobioway Cell Therapy Co., Ltd.Collaborator
- Wenzhou Medical UniversityCollaborator
- Zunyi Medical CollegeCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.